ELIQUIS for initial DVT/PE treatment*—
And for appropriate patients, continue on a low dose † to reduce the risk of
recurrent DVT/PE following initial therapy 1
To learn more about ELIQUIS, visit
hcp.eliquis.com
*Initial therapy: 10 mg, orally twice daily for the fi rst 7 days. After 7 days, 5 mg orally twice daily.
†
Extended therapy: 2.5 mg, orally twice daily. Please see full dosing information in the Prescribing Information.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS (cont’d)
The next dose of ELIQUIS should not be administered earlier
than 5 hours after the removal of the catheter. The risk
may also be increased by traumatic or repeated epidural
or spinal puncture. If traumatic puncture occurs, delay the
administration of ELIQUIS for 48 hours.
Monitor patients frequently and if neurological compromise is
noted, urgent diagnosis and treatment is necessary. Physicians
should consider the potential benefi t versus the risk of
neuraxial intervention in ELIQUIS patients.
• Prosthetic Heart Valves: The safety and effi cacy of ELIQUIS
have not been studied in patients with prosthetic heart valves
and is not recommended in these patients.
• Acute PE in Hemodynamically Unstable Patients or
Patients who Require Thrombolysis or Pulmonary
Embolectomy: Initiation of ELIQUIS is not recommended as an
alternative to unfractionated heparin for the initial treatment
of patients with PE who present with hemodynamic instability
or who may receive thrombolysis or pulmonary embolectomy.
ADVERSE REACTIONS
• The most common and most serious adverse reactions
reported with ELIQUIS were related to bleeding.
TEMPORARY INTERRUPTION FOR SURGERY
AND OTHER INTERVENTIONS
• ELIQUIS should be discontinued at least 48 hours prior to
elective surgery or invasive procedures with a moderate or
high risk of unacceptable or clinically signifi cant bleeding.
ELIQUIS should be discontinued at least 24 hours prior to
elective surgery or invasive procedures with a low risk of
bleeding or where the bleeding would be noncritical in
location and easily controlled. Bridging anticoagulation
during the 24 to 48 hours after stopping ELIQUIS and prior
to the intervention is not generally required. ELIQUIS should
be restarted after the surgical or other procedures as soon
as adequate hemostasis has been established.
DRUG INTERACTIONS
• Strong Dual Inhibitors of CYP3A4 and P-gp: Inhib